Abstract
ABSTRACT: The cerebro-hepato-renal syndrome of Zellweger is a fatal hereditary disease and most of the affected infants die before the age of 6 months. Most probably the fatal outcome of the disease is due to an apparent complete lack of peroxisomes in the liver, kidneys, and brain. Treatment with clofibrate is known to increase drastically the number of peroxisomes in mammalian liver. We therefore treated two infants with the Zellweger syndrome with clofibrate (30 and 45 mg/kg body weight, respectively) for 3–4 wk. No clinical effect of the treatment was observed in any of the two cases, and the pattern of abnormal bile acids in serum did not change. No peroxisomes could be detected by electron microscopy of liver biopsies taken immediately after the treatment. Our failure to induce peroxisomes in the two Zellweger patients is in accord with the hypothesis that the protein missing in this autosomal recessive disease is absolutely essential for the formation of peroxisomes.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Björkhem, I., Blomstrand, S., Glaumann, H. et al. Unsuccessful Attempts to Induce Peroxisomes in Two Cases of Zellweger Disease by Treatment with Clofibrate. Pediatr Res 19, 590–593 (1985). https://doi.org/10.1203/00006450-198506000-00018
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/00006450-198506000-00018
This article is cited by
-
Loss of functional peroxisomes leads to increased mitochondrial biogenesis and reduced autophagy that preserve mitochondrial function
Cellular and Molecular Life Sciences (2023)
-
Peroxisomes in mice fed a diet supplemented with low doses of fish oil
Lipids (1995)
-
Prenatal and perinatal diagnosis of peroxisomal disorders
Journal of Inherited Metabolic Disease (1989)
